Similarly, the GLI1 inhibitor GANT61 in combination with the FLT3-kinase inhibitor sunitinib and PI3K-inhibitor PF-04691502 was shown to downregulate GLI1 expression in and reduce the proliferation and survival of FLT3-mutated AML cells, thereby prolonging the survival of AML xenografts (Latuske et al., 2017). This evidence concerns the gene FLT3 and acute myeloid leukemia.